A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.
Recruiting now. Registry record last updated July 22, 2026.
- Who can join
- Children and teens 12 to 17, have obesity.
- What you take
- orforglipron, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 6.2 years; your own time in it is usually shorter.
- What you get
- Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
What this study is for
Primary condition: Obesity. Also studied in: Overweight.
Full scientific study title: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities.
Who can join
Children and teens 12 to 17, have obesity. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening.
- Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart \[CDC-NCHS, 2022\]); OR
- Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,
- hypertension
- type 2 diabetes (T2D)
Key exclusion criteria
- Prepubertal (Tanner stage 1)
- Have a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kilograms (kg) (11 pounds) within 90 days before screening
- Have undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:
- gastric bypass
- sleeve gastrectomy
Where this trial is enrolling
This trial has 14 sites across 12 states. Contact a site coordinator directly to start screening.
California1 site
- Carey Chronis MD Pediatric, Infant and Adolescent MedicineVentura, California
Connecticut1 site
- Stamford Therapeutics ConsortiumStamford, Connecticut
Georgia1 site
- Children's Healthcare of Atlanta - Center for Advanced PediatricsAtlanta, Georgia
Illinois1 site
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, Illinois
Louisiana1 site
- Velocity Clinical ResearchLafayette, Louisiana
Mississippi1 site
- MedPharmics, LLCGulfport, Mississippi(228) 206-1283
Missouri1 site
- Sundance Clinical ResearchSt Louis, Missouri
North Carolina1 site
- Lucas Research, Inc.Morehead City, North Carolina
Pennsylvania1 site
- Childrens Hospital of PittsburghPittsburgh, Pennsylvania
Tennessee1 site
- Vanderbilt Health One Hundred OaksNashville, Tennessee
Texas3 sites
- Dynamed Clinical Research, LP d/b/a DM Clinical ResearchHouston, Texas
- La Providence Pediatrics Clinic - Chemidox Clinical TrialsHouston, Texas
- Martin Diagnostic ClinicTomball, Texas
Utah1 site
- Velocity Clinical Research, Salt Lake CitySouth Jordan, Utah
Timeline
Started enrolling: November 18, 2024. Expected completion: January 2031. Last updated on ClinicalTrials.gov: July 22, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
